|
| Press Releases |
|
 |
|
| Friday, January 10, 2020 |
|
|
SinoMab Granted the "Most Popular Newly Listed Company" Award |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Group has won the title of the "Most Popular Newly Listed Company" at the 4th Hong Kong Golden Stocks Awards held in Shenzhen. more info >> |
|
| Wednesday, November 20, 2019 |
|
|
类风湿关节炎治疗市场蓝海潜力巨大 中国抗体公布在研药物SM03类风湿关节炎III期临床试验最新进展 |
| 中国抗体制药有限公司（「中国抗体」或「公司」，连同其附属公司，统称「集团」；股份代号：3681.HK），专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司，欣然宣布其旗舰在研药物SM03类风湿关节炎III期临床试验最新进展。 more info >> |
|
|
類風濕關節炎治療市場藍海潛力巨大 中國抗體公佈在研藥物SM03類風濕關節炎III期臨床試驗最新進展 |
| 中國抗體製藥有限公司（「中國抗體」或「公司」,連同其附屬公司，統稱「集團」；股份代號：3681.HK），專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司，欣然宣佈其旗艦在研藥物SM03類風濕關節炎III期臨床試驗最新進展。 more info >> |
|
|
Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA |
| SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce its latest progress of SM03 phase III clinical trial for the treatment rheumatoid arthritis. more info >> |
|
| Monday, November 11, 2019 |
|
|
中国抗体（3681.HK）：商业化进程未来可期 |
| 2018年港交所设立新规，允许未盈利公司在香港主板上市，由此揭开了内地生物科技公司赴港上市热潮的序幕。 more info >> |
|
|
中國抗體（3681.HK）：商業化進程未來可期 |
| 2018年港交所設立新規，允許未盈利公司在香港主板上市，由此揭開了內地生物科技公司赴港上市熱潮的序幕。 more info >> |
|
| Wednesday, October 30, 2019 |
|
|
中国抗体制药宣布于港交所主板上市计划 |
| 中国抗体制药有限公司（「中国抗体制药」或「公司」连同其附属公司，统称「集团」；股份代号：3681.HK），专门研究、发展、制造及商业化免疫性疾病疗法且主要研制以单克隆抗体为基础的生物药的香港生物制药公司，今天宣布于香港联合交易所有限公司（「联交所」）主板上市计划。 more info >> |
|
|
中國抗體製藥宣佈於港交所主板上市計劃 |
| 中國抗體製藥有限公司（「中國抗體製藥」或「公司」連同其附屬公司，統稱「集團」；股份代號：3681.HK），專門研究、發展、製造及商業化免疫性疾病療法且主要研製以單克隆抗體為基礎的生物藥的香港生物製藥公司，今天宣佈於香港聯合交易所有限公司（「聯交所」）主板上市計劃。 more info >> |
|
|
SinoMab BioScience Announces Proposed Listing on the Main Board of SEHK |
| SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
加強管控開支 提升政府效率 繼續投資基建 重塑經濟動力
Feb 26, 2025 21:18 HKT/SGT
|
|
|
HKTDC welcomes Hong Kong SAR's 2025-26 Budget
Feb 26, 2025 19:24 HKT/SGT
|
|
|
Nissin Foods (Hong Kong) Charity Fund Supports Elite Athletes from The Education University of Hong Kong for the Third Consecutive Year
Feb 26, 2025 18:58 HKT/SGT
|
|
|
日清食品（香港）慈善基金連續第三年支持香港教育大學精英運動員
Feb 26, 2025 18:42 HKT/SGT
|
|
|
日清食品（香港）慈善基金连续第三年支持香港教育大学精英运动员
Feb 26, 2025 18:27 HKT/SGT
|
|
|
Q2 Metals Announces Warrant Exercise for $7.6 Million
Feb 26, 2025 16:05 HKT/SGT
|
|
|
CGFNS International 將更名為 TruMerit
Feb 26, 2025 15:00 HKT/SGT
|
|
|
富士通、ビジネスの成長と持続可能な社会の実現を両立するネットポジティブに関する調査「ネットポジティブインデックス調査レポート」を公開
Feb 26, 2025 15:00: JST
|
|
|
雲頂新耀發佈伊曲莫德（VELSIPITY(R)）完整維持期數據 創新研發實力再獲認可
Feb 26, 2025 14:21 HKT/SGT
|
|
|
云顶新耀发布伊曲莫德（VELSIPITY(R)）完整维持期数据 创新研发实力再获认可
Feb 26, 2025 14:18 HKT/SGT
|
|
|
TransNusa Becomes First Indonesian Airline to Launch Scheduled Bali - Guangzhou Route
Feb 26, 2025 13:29: JST
|
|
|
TransNusa Becomes First Indonesian Airline to Launch Scheduled Bali - Guangzhou Route
Feb 26, 2025 12:29 HKT/SGT
|
|
|
三菱重工、オーストラリアのキャンベラにて活動を開始
Feb 26, 2025 11:40: JST
|
|
|
Sevens Atelier records profit for FY 2024, paving the way for accelerated growth and strategic expansion
Feb 26, 2025 11:00 HKT/SGT
|
|
|
Olympus Announces Milestone for iTind(TM) Device with Expanded Availability Across Major APAC Markets
Feb 26, 2025 11:00 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
